We are a health technology company that offers DNA screening for men, women, and their children. Our philosophy is simple: focus on diseases where advanced knowledge makes a difference in health outcomes.
Our team consists of top-tier engineers, scientists, and healthcare professionals who work together to provide people with meaningful health data.
We integrate sophisticated technology with custom automation in our CLIA-approved, CAP-accredited and NYS CLEP-certified medical laboratory.
Counsyl has worked with thousands of providers to screen over half a million patients. The Counsyl platform extends beyond family preparation to include pregnancy screening and inherited cancer screening.
Led by co-founders Ramji Srinivasan, CEO; Eric Evans, Chief Scientist; and Rishi Kacker, VP of Engineering, Counsyl has raised a total of $102M and is privately funded by Founders Fund, Pilot Growth Equity, Goldman Sachs Asset Management, Felicis Ventures, and other prominent investors.
Counsyl has renamed its products effective July 19, 2017. The Family Prep Screen is now the Foresight Carrier Screen. The Informed Pregnancy Screen is now the Prelude Prenatal Screen. The Inherited Cancer Screen is now the Reliant Cancer Screen.
The new names now appear on all communications from Counsyl. If you have any questions, please contact Counsyl directly.